Accutane Exits The Acne Market

By ·
Accutane Exits The Acne Market featured image

After multiple verdicts awarding millions of dollars in damages to sickened patients, Roche is pulling its controversial acne drug Accutane from the U.S. market.

Prescribed for severe acne, often as a last resort, Accutane received FDA approval in 1982. Over the years, it gained a reputation as a high-risk medication with potential side effects such as birth defects, depression and suicide. Most of the lawsuits involved patients who reportedly developed inflammatory bowel disease as a result of Accutane use, their cases underpinned by claims that they were not sufficiently warned of the risk.

Roche, however, says their decision to discontinue American Accutane sales had nothing to do with health hazards.

“Roche stands behind the safety of Accutane and the rigorous risk-management program Roche developed over decades of cooperation with the FDA,” a spokesperson said in a statement. Instead, they point to the financial impact of generic competition as the key factor.

Accutane had already been pulled from the market in Austria, Denmark, France, Germany, Norway, Portugal and Spain.

Tell us about your personal Accutane experience by leaving a comment below.

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.